“For 2023, we are setting an adjusted EBITDA guidance range of $290 million to $320 million with total growth and maintenance capital expenditures of $45 million to $65 million. After normalizing for acquisitions and divestitures in 2022, the midpoint of our guidance range reflects approximately 15% year-over-year growth in adjusted EBITDA and a resumption of drilling and completion activity that is much more in line with our longer-term expectations for our business. We expect to continue to de-lever the balance sheet towards an approximate 4.35x leverage ratio by year end1. We also remain very optimistic about our opportunity set to further execute on strategic and credit-accretive acquisitions and divestitures, commercializing Double E, and capturing new commercial opportunities in the DJ and other core basins that will take advantage of the capacity behind our operating systems.”
NantHealth Q2 EPS $(0.10) Misses $(0.09) Estimate, Sales $16.50M Miss $17.01M Estimate
NantHealth (NASDAQ:NH) reported quarterly earnings of $0.10 per share. This is a 225 percent increase over losses of $(0.08) per share from the same period last year. The company reported $16.50 million in sales this quarter. This is a 2.55 percent increase over sales of $16.09 million the same period last year.
